Skip to contentN
Nautilus Biotechnology, Inc.
N
NAUTNautilus Biotechnology, Inc. Q2 2025 · 10-Q
Revenue$0.00$0.00no prior Q2 2024 on file Net Income-$15.03M-$15.03MN/M vs Q2 2024 EPS Diluted-$0.12-$0.12N/M vs Q2 2024 Operating Cash Flowderived-$13,350,000N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nautilus Biotechnology, Inc. · CIK 1808805 · Engraved from SEC EDGAR
Free Cash Flowderived-$13,746,000N/M ended Jun 30, 2025 · filed Jul 31, 2025 · 31 d after period end